Search

Your search keyword '"Haegert, Anne"' showing total 92 results

Search Constraints

Start Over You searched for: Author "Haegert, Anne" Remove constraint Author: "Haegert, Anne" Database Unpaywall Remove constraint Database: Unpaywall
92 results on '"Haegert, Anne"'

Search Results

2. Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma

3. Supplementary Figure 1 from Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target

4. Data from Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications

5. Data from Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target

6. Data from Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications

7. Supplementary Data from Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications

8. Supplementary Data from Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications

9. Supplementary Table 5 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

10. Supplementary Table S1 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

11. Supplementary figure S2 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

12. Supplementary Figure 1 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

13. Supplementary Data from Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability

14. Supplementary Data from Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability

15. Supplementary Table 2 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

16. Supplementary Data from Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability

17. Supplementary Table S2 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

18. Data from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer

19. Supplementary Table S3 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

20. Supplementary Information from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer

21. Supplementary figure S4 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

22. Data from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer

23. Supplementary Table 1 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

24. Supplementary Table S1 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

25. Supplementary figure S3 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

26. Supplementary Data from Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability

27. Supplementary Information from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer

28. Supplementary figure legends from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

29. Supplementary figure S7 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

30. Supplementary figure S5 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

31. Supplementary figure S6 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

32. Supplementary figure S1 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

33. Supplementary Table 3 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

34. Supplementary Figures 1 - 9 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

35. Data from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

36. Supplementary Table 1 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

37. Supplementary Figures 1 - 9 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

38. Supplementary Table 2 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

39. Data from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

40. Supplementary Table 1 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

41. Supplementary Table 2 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

42. Supplementary Table 3 from High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

44. Patient and cell-type specific hiPSC-modeling of a truncating titin variant associated with atrial fibrillation

47. Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications

48. Cobalt ions induce metabolic stress in synovial fibroblasts and secretion of cytokines/chemokines that may be diagnostic markers for adverse local tissue reactions to hip implants

50. Novel Lignin-Capped Silver Nanoparticles against Multidrug-Resistant Bacteria

Catalog

Books, media, physical & digital resources